Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

CSL Behring124 enrolled

Overview

This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

124

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

Garadacimab, Factor XIIa Antagonist Monoclonal AntibodyBIOLOGICAL

Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously

PlaceboDRUG

CSL312 diluent administered intravenously

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection as determined using a molecular diagnostic test (reverse transcription polymerase chain reaction \[RT-PCR\] or equivalent) approved by regulatory authorities (including Food and Drug Administration or Brazilian Health Regulatory Agency) or allowed under an emergency use authorization within 14 days before Screening. If a false negative result is suspected, the SARS-CoV-2 test may be repeated within the Screening Period. * Chest CT scan or X ray results confirming interstitial pneumonia * Severe COVID 19 disease as evidenced by ≥ 1 of the following criteria at Screening including within 24 hours before Screening: * Respiratory frequency \> 30 breaths per minute * SpO2 ≤ 93% on room air * Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) \< 300 * Ratio of Arterial oxygen saturation to fraction of inspired oxygen (SaO2/FiO2 ratio) \< 218 (if PaO2/FiO2 ratio is not available) * Radiographic lung infiltrates \> 50% Exclusion Criteria: * Currently enrolled, planning to enroll, or participated, within the last 30 days, in a clinical study requiring administration of an IP, including expanded access or compassionate use with the only exception being administration of convalescent plasma. Administration of IP is permitted only if an emergency use authorization has been granted (eg, remdesivir). Additionally, off label use of approved drugs (eg, anti IL 6/anti IL 6R) is also permitted. * Pregnant or breastfeeding (female subjects) * Intubated and require mechanical ventilation (including ECMO) at the time of randomization * In the opinion of the investigator, the subject is expected to be intubated in the first 24 hours after IMP administration * Has a Do-Not-Intubate (DNI) or Do-Not-Resuscitate (DNR) order * In the opinion of the investigator, not expected to survive for \> 48 hours after admission * Presence of any of the following comorbid conditions prior to randomization and prior to SARS CoV 2 infection: * Severe heart failure (New York Heart Association Class IV) * End stage renal disease (Stage ≥ 4) or need for renal replacement therapy * Biopsy confirmed cirrhosis, portal hypertension, or hepatic encephalopathy * Malignancy (Stage IV) * Chronic lung disease requiring the use of oxygen at home * Active tuberculosis disease * Active bleeding or a current clinically significant coagulopathy (eg, international normalized ratio \[INR\] \> 1.5) or clinically significant risk for bleeding (eg, recent intracranial hemorrhage or bleeding peptic ulcer within the last 4 weeks) * History of venous thrombosis, myocardial infarction or cerebrovascular event within 3 months, or a prothrombotic disorder (eg, antithrombin III, protein C or protein S deficiency) * Known or suspected Grade 3 or 4 infusion-related reaction or hypersensitivity (per Common Terminology Criteria for Adverse Events \[CTCAE\]) to monoclonal antibody therapy, or hypersensitivity to the IMP or any excipients of the IMP * Currently receiving a therapy not permitted during the study. * Female subject of childbearing potential or fertile male subject either not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 90 days after receipt of the last dose of IMP * Any clinical or laboratory abnormality or other underlying conditions (eg, psychological disorders, substance abuse) that would render the subject unsuitable for participation in the study, in the opinion of the investigator

Locations (14)

Nova Clinical Research, LLC

Bradenton, Florida, United States

Theia Clinical Research, LLC

St. Petersburg, Florida, United States

Outcomes

Primary Outcomes

The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation

Time frame: From randomization to Day 28

Secondary Outcomes

Percent of Participants With Death From All Causes

Time frame: From randomization to Day 28

Percent of Participants With Tracheal Intubation

Time frame: From randomization to Day 28

Number of Participants With ≥ 2-Point Improvement Compared to Baseline on National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Scale

The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.

Time frame: From randomization to Day 28

Percent of Participants With ≥ 2-Point Improvement Compared to Baseline on NIAID

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

MercyOne North Iowa Medical Center

Mason City, Iowa, United States

Northeast Iowa Medical Education Foundation

Waterloo, Iowa, United States

Lahey Hospital and Medical Center

Burlington, Massachusetts, United States

University of Mississippi Medical Center

Jackson, Mississippi, United States

Holy Name Hospital

Teaneck, New Jersey, United States

Inspira Health Center Vineland

Vineland, New Jersey, United States

Sisters of Charity Hospital/ St. Joseph's Campus

Buffalo, New York, United States

Carolina Institute for Clinical Research

Fayetteville, North Carolina, United States

...and 4 more locations

Time frame: From randomization to Day 28

Number of Participants Within Each of the Categories of the NIAID at End of Study

Time frame: Day 28

Percent of Participants Within Each of the Categories of the NIAID at End of Study

Time frame: Day 28

Percent of Participants Requiring Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP)

Time frame: From randomization to Day 28

Percent of Participants Requiring Extracorporeal Membrane Oxygenation (ECMO)

None of the enrolled subjects required the use of ECMO during their participation in this study. Therefore, no data to report for this outcome measure.

Time frame: From randomization to Day 28

Percent of Participants Requiring High-Flow Nasal Cannula (HFNC)

Time frame: From randomization to Day 28

Maximum Change From Baseline in Sequential Organ Failure Assessment (SOFA) Score

The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Each system is scored from 0 (normal function) to 4 (most abnormal) with a total score ranging from 0 to 24. A high total SOFA score have been shown to be related to a worse outcome.

Time frame: From randomization to Day 28

Change From Baseline in SOFA Total Score

Time frame: From randomization to Day 28

Change From Baseline in the Individual Components of SOFA Score

Time frame: From randomization to Day 28

Length of Hospital Stay

Time frame: From randomization to Day 28 (+/- 2 days)

Number of Participants Experiencing Adverse Events (AEs)

Time frame: Up to 28 days after CSL312 or placebo administration

Percent of Participants Experiencing AEs

Time frame: Up to 28 days after CSL312 or placebo administration

Number of Participants Experiencing Serious Adverse Events (SAEs)

Time frame: Up to 28 days after CSL312 or placebo administration

Percent of Participants Experiencing SAEs

Time frame: Up to 28 days after CSL312 or placebo administration

Number of Participants With Adverse Events of Special Interest (AESIs)

Time frame: Up to 28 days after CSL312 or placebo administration

Percent of Participants With AESIs

Time frame: Up to 28 days after CSL312 or placebo administration

Number of Participants With Anti-CSL312 Antibodies

Time frame: Up to 28 days after CSL312 or placebo administration

Maximum Plasma Concentration (Cmax) of CSL312

Time frame: Up to 28 days after CSL312 administration

Time to Maximum Plasma Concentration (Tmax) of CSL312

Time frame: Up to 28 days after CSL312 administration

Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-Last) of CSL312

Time frame: Up to 28 days after CSL312 administration

Terminal Half-life (T1/2) of CSL312

Time frame: Up to 28 days after CSL312 administration